The training of academic medical oncologists with expertise in basic, translational, clinical and health services research remains an important priority for academic medical centers throughout the United States. This task has become increasingly critical as the discipline of medical oncology translates basic science principles into clinical practice. The UCLA Hematology/Oncology clinical fellowship program aims at offering high quality comprehensive clinical and research training for medical oncologists. The program has excelled in the training of academic medical oncologists in the past 30 years, having generated several of the success stories in medical oncology and trained investigators that have reached the highest levels in academic ranks in several institutions. The Hematology/Oncology fellowship training program includes an initial year of full time clinical training with inpatient and outpatient rotations to fulfill the subspeciality board requirements for certification eligibility in Medical Oncology. Salary support for this initial clinical period is derived from Divisional and University funds. From the pool of Hematology/Oncology fellows we select 2-3 fellows per year to be included in the 24 month "Academic Training in Medical Oncology" (abbreviated as Oncology T32), for which we request funding in this proposal. This is a second revised application. In this submission we have made major changes in the training program that arise from the prior review cycles: The Director has been changed from Dennis Slamon, M.D., Ph.D., to Antoni Ribas, M.D., Ph.D. The main reason is to refocus the program to foster the training of physician-scientists in oncology research. The training faculty has been markedly changed. We have used new selection criteria for the training faculty (mainly peer reviewed funding, independent research programs and experience as mentors), which has resulted a marked decrease in the proposed faculty (from 55 to 29), of whom half are newly appointed training faculty. The Oncology T32 is re-organized into 3 training tracks, basic, translational and clinical research, with different faculty and curriculum for each track and defined criteria for the determination of success of trainees and mentors. The fellowship program has had recent success in attracting underrepresented minority (URM) trainees. Newly proposed plans to increase URM in the program include a proactive approach in the selection of URM and the addition of mentors with a track record of training URM.
fSee instructions!: The Oncology T32 training program is aimed at the training new generations of ethnically-diverse physician- scientists conducting patient-oriented oncology research by offering 2 years of basic, translational or clinical cancer-focused research.
|Ribas, Antoni; Shin, Daniel Sanghoon; Zaretsky, Jesse et al. (2016) PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res 4:194-203|
|Hsu, Melody S; Sedighim, Shaina; Wang, Tina et al. (2016) TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunol Res 4:412-8|
|Zaretsky, Jesse M; Garcia-Diaz, Angel; Shin, Daniel S et al. (2016) Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med 375:819-29|
|Hu-Lieskovan, Siwen; Mok, Stephen; Homet Moreno, Blanca et al. (2015) Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med 7:279ra41|
|Shin, Daniel Sanghoon; Ribas, Antoni (2015) The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol 33:23-35|
|Larson, Sarah; De Oliveira, Satiro N (2014) Gene-modified hematopoietic stem cells for cancer immunotherapy. Hum Vaccin Immunother 10:982-5|
|Hu-Lieskovan, Siwen; Robert, Lidia; Homet Moreno, Blanca et al. (2014) Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol 32:2248-54|
|Toy, Gerald; Austin, Wayne R; Liao, Hsiang-I et al. (2010) Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci U S A 107:5551-6|
|Singh, A S; Radu, C G; Ribas, A (2010) PET imaging of the immune system: immune monitoring at the whole body level. Q J Nucl Med Mol Imaging 54:281-90|
|Matei, Daniela; Chang, David D; Jeng, Meei-Huey (2004) Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 10:681-90|
Showing the most recent 10 out of 13 publications